<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Mol Hepatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Clin Mol Hepatol</journal-id>
      <journal-id journal-id-type="publisher-id">CMH</journal-id>
      <journal-title-group>
        <journal-title>Clinical and molecular hepatology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2287-2728</issn>
      <issn pub-type="epub">2287-285X</issn>
      <publisher>
        <publisher-name>The Korean Association for the Study of the Liver</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23837144</article-id>
      <article-id pub-id-type="pmc">3701852</article-id>
      <article-id pub-id-type="doi">10.3350/cmh.2013.19.2.185</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Liver Pathology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>&#x3B2;-catenin activated hepatocellular adenoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chu</surname>
            <given-names>Hyun Hee</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Moon</surname>
            <given-names>Woo Sung</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
      </contrib-group>
      <aff id="A1">Department of Pathology and Research Institute for Endocrine Science, Chonbuk National University Medical School, Jeonju, Korea.</aff>
      <author-notes>
        <corresp>Corresponding author: Woo Sung Moon. Department of Pathology, Chonbuk National University Medical School, 567 Baekje-daero, Deokjin-gu, Jeonju 561-756, Korea. Tel. +82-63-270-3086, Fax. +82-63-270-3135, <email>mws@chonbuk.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>6</month>
        <year>2013</year>
      </pub-date>
      <volume>19</volume>
      <issue>2</issue>
      <fpage>185</fpage>
      <lpage>189</lpage>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2013 by The Korean Association for the Study of the Liver</copyright-statement>
        <copyright-year>2013</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <kwd-group>
        <kwd>Hepatocellular adenoma</kwd>
        <kwd>&#x3B2;-catenin activated</kwd>
        <kwd>Hepatocelluar carcinoma</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Hepatocellular adenoma (HCA) is a benign liver tumor composed of hepatocytes.<xref ref-type="bibr" rid="B1">1</xref> HCA represents a heterogeneous entity, and is subclassified into four groups according to genotype and phenotype: hepatocyte nuclear factor (HNF) 1&#x3B1;-inactivated HCA, &#x3B2;-catenin-activated HCA, inflammatory HCA, and unclassified HCA.<xref ref-type="bibr" rid="B1">1</xref> Theses subtypes vary greatly in their clinical and pathological features. Identifying the HCA subtype is important because it represents a way to understand the prognosis of HCA in terms of hepatocellular carcinoma (HCC) transformation. We present a case of &#x3B2;-catenin-activated HCA and discuss the histopathological findings with a review of the literature.</p>
    </sec>
    <sec>
      <title>CASE SUMMARY</title>
      <p>A 39-year-old man was admitted to our hospital to evaluate an asymptomatic hepatic mass detected incidentally during a health checkup. The patient did not have a history of alcoholism, androgenic steroid use, or metabolic syndrome. The subject's body mass index (BMI, kg/m<sup>2</sup>) was 20.7 (normal range, 18.50-24.99 kg/m<sup>2</sup>). Serum aspartate aminotransferase was 21 IU/L (normal range, 12-33 IU/L), alanine aminotransferase was 14 IU/L (normal range, 5-35 IU/L), and gamma-glutamyl transferase (GGT) was 31 IU/L (normal range, 12-73 IU/L). Other liver function tests were within normal limits. Hepatitis B virus surface antigen was negative, and the levels of tumor markers were all within normal ranges. Magnetic resonance imaging demonstrated a lobulated contoured hepatic mass located in segment VI that showed iso-intensity on T1-weighted images, heterogeneous high-intensity on T2-weighted images, and a focal signal drop, particularly at the periphery, on fat-suppressed T2-weighted images (<xref ref-type="fig" rid="F1">Fig. 1A</xref>), suggesting hepatocellular adenoma. A laparoscopic wedge resection was performed.</p>
    </sec>
    <sec>
      <title>PATHOLOGICAL FINDINGS</title>
      <p>A 5.2&#xD7;3.6 cm sized, homogeneous, green colored hepatic mass was observed on the cut section (<xref ref-type="fig" rid="F1">Fig. 1B</xref>). The margins of the mass were relatively well-defined but not encapsulated. The mass was microscopically composed of benign hepatocytes arranged in one or two thick irregular cell plates with sharp demarcation from the surrounding non-tumoral liver (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). The background liver was normal. Other characteristic pathological features of this mass included peliosis (<xref ref-type="fig" rid="F2">Fig. 2B</xref>), sinusoidal dilatation and inflammatory infiltrates (<xref ref-type="fig" rid="F2">Fig. 2C</xref>), diffuse steatosis (<xref ref-type="fig" rid="F2">Fig. 2D</xref>), cytoplasmic bile pigment and feathery degeneration of hepatocytes (<xref ref-type="fig" rid="F2">Fig. 2E</xref>), numerous unpaired arteries, and bile duct loss. An occasional pseudoglandular growth pattern and cytologic atypia were also observed (<xref ref-type="fig" rid="F2">Fig. 2F</xref>). Immunohistochemistry revealed that the tumor cells were positive for glutamine synthetase (GS) in a diffuse pattern (<xref ref-type="fig" rid="F3">Fig. 3A</xref>) and showed aberrant cytoplasmic and nuclear &#x3B2;-catenin expression (<xref ref-type="fig" rid="F3">Fig. 3B</xref>). The tumor cells were negative for two inflammation-related proteins, serum amyloid A and C reactive protein (SAA/CRP) and also negative for glypican 3. The final diagnosis was &#x3B2;-catenin-activated HCA based on the histological and immunohistochemical findings. No obvious recurrence of the tumor was detected post-operatively during the 7 month follow-up.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>HCA is a rare benign liver tumor (solitary or multiple) that most frequently develops in young women who are using oral contraceptives (OC). HCA is rare in children, men, and the elderly.<xref ref-type="bibr" rid="B1">1</xref> Most men developing HCA have been users of anabolic steroids for bodybuilding.<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref> Patients taking androgens for Fanconi anemia or acquired aplastic anemia are also at risk.<xref ref-type="bibr" rid="B2">2</xref> Obesity and alcohol intake have recently been shown to be risk factors for developing inflammatory HCA.<xref ref-type="bibr" rid="B3">3</xref> HCA can also occur in specific settings such as metabolic disease (glycogenosis, tyrosinemia, or galactosemia) but rarely in association with polycystic ovary syndrome or advanced-stage fatty liver disease.<xref ref-type="bibr" rid="B4">4</xref> Some small HCA may regress after withdrawal of OC or after menopause; however, they usually remain stable, or increase in size. Clinically significant hemorrhaging is observed in 20-25% of cases. Malignant transformation to HCC is rare but well-documented.<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref></p>
      <p>HCA are classified into three main subgroups according to genotype: (1) inactivating mutations in the <italic>HNF 1&#x3B1;</italic> gene, (2) activating mutation in the <italic>CTNNB1</italic> gene that encodes &#x3B2;-catenin, and (3) activation of signal transducers and activators of transcription type 3 in the absence of ligand due to glycoprotein 130 mutants.<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref> A phenotypic classification is based on features of morphology and immunohistochemistry. Close relationships have been found between these molecular subgroups defined by genotype and their clinicopathological characteristics.<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref> This new genotype/phenotype subclassification of HCA was introduced by Bioulac-Sage and colleagues and is currently presented by the WHO Tumors of the Digestive System.<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref> The <italic>HNF 1&#x3B1;</italic> biallelic somatic mutation is observed in 35-40% of HCA cases. It almost always occurs in women. HNF 1&#x3B1;-inactivated HCA is most highly steatotic, with a lack of expression of liver fatty acid binding protein (LFABP) in immunohistochemistry analyses. Significant inflammation and cellular atypia are absent. A <italic>HNF 1&#x3B1;</italic> germline mutation is observed in &lt;5% of HCA cases and can be associated with MODY 3 diabetes, particularly in children and young adults. The diagnosis of HNF 1&#x3B1;-inactivated HCA may be suggested by a radiologist due to the steatosis. The second type, an activating &#x3B2;-catenin mutation, is found in 10-15% HCA cases. This &#x3B2;-catenin activated HCA subtype is often associated with males as in our case or specific conditions (glycogenosis or administration of male hormone). Cytologic atypia and a pseudoglandular growth pattern are frequently observed. Immunohistochemistry studies show that this HCA subtype overexpresses &#x3B2;-catenin (nuclear and cytoplasmic) and GS. Because this group has a higher risk of malignant transformation into HCC than that of other subtypes, identifying &#x3B2;-catenin activated HCA subtype is extremely important. The third, inflammatory HCA, is observed in 45-60% of cases, and most patients with this subtype are women. Lesions are characterized by inflammatory infiltrates, thick-walled arteries, sinusoidal dilatation, and a ductular reaction. Inflammatory HCA is immunohistochemically characterized by increased expression of SAA/CRP at both the mRNA and protein levels. GS is usually absent, and LFABP is normally expressed in the non-tumoral liver parenchyma. GGT is frequently elevated in this group, with a biological inflammatory syndrome present. Additionally, more overweight patients (BMI &gt;25) are found in this group. A risk for malignant transformation is present, particularly for cases in which &#x3B2;-catenin is also mutated. Finally, &lt;10% of HCA is unclassified with non-mutated HNF 1&#x3B1; or &#x3B2;-catenin and without an inflammatory infiltrate.</p>
      <p>van Aalten et al reported that the subtype classification was straightforward in &gt;90% of HCA cases using the immunohistochemical staining pattern and morphology.<xref ref-type="bibr" rid="B8">8</xref> Our case showed diffuse and strong positivity for GS and aberrant cytoplasmic and nuclear staining for &#x3B2;-catenin, so the diagnosis of &#x3B2;-catenin-activated HCA was made by immunohistochemistry (<xref ref-type="table" rid="T1">Table 1</xref>). However, the present case exhibited some unusual histological features such as diffuse steatosis, inflammatory infiltrates, and peliosis, which usually appear in inflammatory HCA. Therefore, our case should be distinguished from &#x3B2;-catenin-activated inflammatory HCA. Steatosis and inflammation are usually absent in &#x3B2;-catenin-activated HCA.<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref> However, Bordeaux's group has pointed out that &#x3B2;-catenin-activated HCA and inflammatory HCA have overlapping features of an inflammatory infiltrate, patchy steatosis, diffuse GS staining, and &#x3B2;-catenin mutation.<xref ref-type="bibr" rid="B3">3</xref> Inflammatory HCA is characterized by diffuse, strong expression of SAA or CRP in tumoral hepatocytes.<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref> These markers are useful for distinguishing cases with overlapping histological features.<xref ref-type="bibr" rid="B10">10</xref> We excluded inflammatory HCA because no SAA/CRP expression was observed, which is necessary for a diagnosis of inflammatory HCA.</p>
      <p>Despite that radiological imaging techniques have made great progress in identifying benign liver tumors, it is difficult to distinguish between different types of HCA (particularly &#x3B2;-catenin-activated HCA, which has variable and nonspecific radiologic findings).<xref ref-type="bibr" rid="B11">11</xref> Complete surgical removal and a careful pathological examination are necessary to prevent a potential misdiagnosis and identify &#x3B2;-catenin-activated HCA, which is prone to develop into HCC.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>The authors have no conflicts to disclose.</p>
      </fn>
    </fn-group>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>BMI</term>
          <def>
            <p>body mass index</p>
          </def>
        </def-item>
        <def-item>
          <term>GGT</term>
          <def>
            <p>gamma-glutamyl transferase</p>
          </def>
        </def-item>
        <def-item>
          <term>GS</term>
          <def>
            <p>glutamine synthetase</p>
          </def>
        </def-item>
        <def-item>
          <term>HCA</term>
          <def>
            <p>hepatocellular adenomas</p>
          </def>
        </def-item>
        <def-item>
          <term>HCC</term>
          <def>
            <p>hepatocelluar carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>HNF 1&#x3B1;</term>
          <def>
            <p>hepatocyte nuclear factor 1&#x3B1;</p>
          </def>
        </def-item>
        <def-item>
          <term>LFABP</term>
          <def>
            <p>liver fatty acid binding protein</p>
          </def>
        </def-item>
        <def-item>
          <term>OC</term>
          <def>
            <p>oral contraceptives</p>
          </def>
        </def-item>
        <def-item>
          <term>SAA/CRP</term>
          <def>
            <p>serum amyloid A/C reactive protein</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Bioulac-Sage</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Balabaud</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wanless</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <chapter-title>Focal nodular hyperplasia and hepatocellular adenoma</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Bosman</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Carneiro</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hruban</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Theise</surname>
              <given-names>ND</given-names>
            </name>
          </person-group>
          <source>WHO Classification of Tumours of the Digestive System</source>
          <edition>4th Ed</edition>
          <publisher-loc>Lyon, France</publisher-loc>
          <publisher-name>IARC Press</publisher-name>
          <year>2010</year>
          <fpage>198</fpage>
          <lpage>204</lpage>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Velazquez</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Alter</surname>
              <given-names>BP</given-names>
            </name>
          </person-group>
          <article-title>Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions</article-title>
          <source>Am J Hematol</source>
          <year>2004</year>
          <volume>77</volume>
          <fpage>257</fpage>
          <lpage>267</lpage>
          <pub-id pub-id-type="pmid">15495253</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bioulac-Sage</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rebouissou</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Blanc</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Saric</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sa Cunha</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry</article-title>
          <source>Hepatology</source>
          <year>2007</year>
          <volume>46</volume>
          <fpage>740</fpage>
          <lpage>748</lpage>
          <pub-id pub-id-type="pmid">17663417</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bioulac-Sage</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cubel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Balabaud</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Pathological diagnosis of hepatocellular adenoma in clinical practice</article-title>
          <source>Diagn Histopathol (Oxf)</source>
          <year>2011</year>
          <volume>17</volume>
          <fpage>521</fpage>
          <lpage>529</lpage>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bioulac-Sage</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Laumonier</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Couchy</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Le Bail</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sa Cunha</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rullier</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience</article-title>
          <source>Hepatology</source>
          <year>2009</year>
          <volume>50</volume>
          <fpage>481</fpage>
          <lpage>489</lpage>
          <pub-id pub-id-type="pmid">19585623</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Micchelli</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Vivekanandan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Boitnott</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Pawlik</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Choti</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Torbenson</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Malignant transformation of hepatic adenomas</article-title>
          <source>Mod Pathol</source>
          <year>2008</year>
          <volume>21</volume>
          <fpage>491</fpage>
          <lpage>497</lpage>
          <pub-id pub-id-type="pmid">18246041</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zucman-Rossi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jeannot</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nhieu</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Scoazec</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Guettier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rebouissou</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC</article-title>
          <source>Hepatology</source>
          <year>2006</year>
          <volume>43</volume>
          <fpage>515</fpage>
          <lpage>524</lpage>
          <pub-id pub-id-type="pmid">16496320</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Aalten</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Verheij</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Terkivatan</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dwarkasing</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>de Man</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Ijzermans</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
          <article-title>Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice</article-title>
          <source>J Hepatol</source>
          <year>2011</year>
          <volume>55</volume>
          <fpage>120</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="pmid">21145863</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van der Borght</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Libbrecht</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Katoonizadeh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aerts</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nevens</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Verslype</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy</article-title>
          <source>Histopathology</source>
          <year>2007</year>
          <volume>51</volume>
          <fpage>855</fpage>
          <lpage>856</lpage>
          <pub-id pub-id-type="pmid">17903198</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bioulac-Sage</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cubel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Balabaud</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zucman-Rossi</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers</article-title>
          <source>Semin Liver Dis</source>
          <year>2011</year>
          <volume>31</volume>
          <fpage>91</fpage>
          <lpage>103</lpage>
          <pub-id pub-id-type="pmid">21344354</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laumonier</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bioulac-Sage</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zucman-Rossi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Balabaud</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Trillaud</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification</article-title>
          <source>Hepatology</source>
          <year>2008</year>
          <volume>48</volume>
          <fpage>808</fpage>
          <lpage>818</lpage>
          <pub-id pub-id-type="pmid">18688875</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>(A) Focal areas of signal loss at the periphery on fat-suppressed T2-weighted images. (B) Cut section of the gross specimen showed well-demarcated, greenish mass-like lesion without hemorrhage or cystic change.</p>
      </caption>
      <graphic xlink:href="cmh-19-185-g001"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <p>(A) The margin of the mass was non-encapsulated, and had a sharp demarcation (arrows) from the surrounding non-tumoral liver (hematoxylin and eosin [H &amp; E] stain, &#xD7;40). The histological examination showed (B) peliosis (H &amp; E stain, &#xD7;100), (C) sinusoidal dilatation and inflammatory infiltrates (H &amp; E stain, &#xD7;200), and (D) steatotic hepatocytes (H &amp; E stain, &#xD7;400). (E) Cytoplasmic bile pigment, feathery degeneration (H &amp; E stain, &#xD7;400), (F) an occasional pseudoglandular growth pattern and cytologic atypia (H &amp; E stain, &#xD7;400) were also observed.</p>
      </caption>
      <graphic xlink:href="cmh-19-185-g002"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Figure 3</label>
      <caption>
        <p>(A) Glutamine synthetase was strongly and diffusely expressed by tumoral hepatocytes (&#xD7;200), and (B) Aberrant cytoplasmic and nuclear expression of &#x3B2;-catenin by tumoral hepatocytes (arrows) (&#xD7;400).</p>
      </caption>
      <graphic xlink:href="cmh-19-185-g003"/>
    </fig>
    <table-wrap id="T1" orientation="portrait" position="float">
      <label>Table 1</label>
      <caption>
        <p>Clinicohistopathological features of hepatocellular adenoma (HCA)<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref></p>
      </caption>
      <graphic xlink:href="cmh-19-185-i001"/>
      <table-wrap-foot>
        <fn>
          <p><sup>*</sup>10% of HCA also have mutant &#xDF;-catenin; <sup>&#x2020;</sup>Except if &#xDF;-catenin is mutated; <sup>&#x2021;</sup>Aberrant cytoplasmic and nuclear expression.</p>
          <p>Grading: +, mild; 2+, moderate; 3+, severe; -, absent.</p>
          <p>HNF 1a, hepatocyte nuclear factor 1; SAA/CRP, serum amyloid A and C reactive protein; BMI, body mass index; ND, not done.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
